{"id":"NCT00953147","sponsor":"Sumitomo Pharma America, Inc.","briefTitle":"A 6 Month Safety and Efficacy Study of Once Daily Ciclesonide Hydrofluoroalkane (HFA) in the Treatment of Perennial Allergic Rhinitis (PAR) in Subjects 12 Years and Older","officialTitle":"A 6-Month Randomized, Double-Blind, Placebo-Controlled, Parallel Group, Efficacy and Safety Study of Once Daily Ciclesonide HFA Nasal Aerosol (80 and 160 Î¼g) in The Treatment of Perennial Allergic Rhinitis (PAR) in Subjects 12 Years and Older","status":"COMPLETED","phase":"PHASE3","dates":{"start":"2009-08","primaryCompletion":"2010-01","completion":"2010-05","firstPosted":"2009-08-06","resultsPosted":"2012-06-07","lastUpdate":"2012-06-13"},"enrollment":1110,"design":{"allocation":"RANDOMIZED","model":"PARALLEL","masking":"QUADRUPLE","primaryPurpose":"TREATMENT"},"conditions":["Allergic Rhinitis","Perennial Allergic Rhinitis"],"interventions":[{"type":"DRUG","name":"Ciclesonide HFA 80 mcg","otherNames":[]},{"type":"DRUG","name":"Ciclesonide HFA 160 mcg","otherNames":[]},{"type":"DRUG","name":"Placebo","otherNames":[]}],"arms":[{"label":"Ciclesonide HFA 80 mcg once daily","type":"EXPERIMENTAL"},{"label":"Ciclesonide HFA 160 mcg once daily","type":"EXPERIMENTAL"},{"label":"Placebo once daily","type":"PLACEBO_COMPARATOR"}],"summary":"This is a 6-month multi-center, randomized, double-blind, placebo-controlled, parallel group, efficacy and safety study of ciclesonide HFA nasal aerosol administered once-daily to male and female subjects 12 years or older diagnosed with perennial allergic rhinitis (PAR).","primaryOutcome":{"measure":"Change From Baseline in Daily Subject-reported AM and PM Reflective TNSS (rTNSS) Averaged Over the First 6 Weeks of Double-blind Treatment","timeFrame":"Weeks 0-6","effectByArm":[{"arm":"Ciclesonide HFA 80 Mcg Once Daily","deltaMin":-1.97,"sd":0.13},{"arm":"Ciclesonide HFA 160 Mcg Once Daily","deltaMin":-1.82,"sd":0.1},{"arm":"Placebo Once Daily","deltaMin":-1.28,"sd":0.13}],"pValues":[{"comp":"OG000 vs OG002","p":"<0.0001"},{"comp":"OG001 vs OG002","p":"0.0005"}]},"eligibility":{"minAge":"12 Years","sex":"ALL","healthyVolunteers":false,"inclusionCount":7,"exclusionCount":17},"locations":{"siteCount":45,"countries":["United States"]},"refs":{"pmids":["22370530"],"seeAlso":[]},"adverseEventsSummary":{"seriousAny":{"events":6,"n":298},"commonTop":["Upper respiratory tract infection","Epistaxis","Nasopharyngitis","Sinusitis","Headache"]}}